Literature DB >> 30776089

The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.

Ashley M Reilly1, Michelle X Ding2, Joseph E Rower3, Tyree H Kiser4.   

Abstract

Concern for bacterial resistance and treatment failure with vancomycin trough concentrations < 10 μg/mL have led guidelines to increase goal concentrations. There is a paucity of data evaluating vancomycin dosage necessary to achieve goals in the neonatal intensive care unit (NICU). We aimed to evaluate the implementation of a new vancomycin dosing guideline in improving trough target attainment. This retrospective study evaluated neonates in the NICU treated with vancomycin between January 2009 and December 2015. Therapeutic trough concentration attainment (10-20 μg/mL) was compared between neonates receiving vancomycin per old versus new dosing guidelines. Vancomycin trough concentrations, modeled pharmacodynamic target attainment, and nephrotoxicity were compared between groups. A total of 212 vancomycin trough concentrations (n = 91 old and n = 121 new guideline) were evaluated in 182 unique neonates. The mean ± standard deviation trough concentration achieved was 18.0 ± 7.3 μg/mL vs 8.9 ± 4.8 μg/mL in the new and old guidelines, respectively (P < .01). The new guideline resulted in a higher percentage of neonates achieving trough concentrations of 10 to 20 μg/mL (62% vs 29%; P < .01) and decreased the percentage of neonates with subtherapeutic trough concentrations (9% vs 69%; P < .01). Pharmacokinetic modeling identified postmenstrual age, days of life, and urine output as predictors of vancomycin clearance and resultant trough and area under the curve values (P < .01 for all). Trough concentrations >10 μg/mL ensured area under the curve /minimum inhibitory concentration >400 in >90% of neonates when bacteria minimum inhibitory concentration was ≤ 1 μg/mL. Nephrotoxicity was similar between groups (8.3% vs 7.7%; P = .99). In conclusion, a vancomycin nomogram designed to achieve trough concentration of 10 to 20 μg/mL improves pharmacodynamic target attainment in neonates in the NICU.
© 2019, The American College of Clinical Pharmacology.

Entities:  

Keywords:  dosing guideline; neonatal; therapeutic drug monitoring; vancomycin

Year:  2019        PMID: 30776089     DOI: 10.1002/jcph.1392

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

2.  Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.

Authors:  Erin Chung; Jonathan Sen; Priya Patel; Winnie Seto
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 6.447

3.  Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation.

Authors:  Bu-Fan Yao; Yue-E Wu; Bo-Hao Tang; Guo-Xiang Hao; Evelyne Jacqz-Aigrain; John van den Anker; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2022-05-06       Impact factor: 5.577

4.  Vancomycin Prescribing Practices and Therapeutic Drug Monitoring for Critically Ill Neonatal and Pediatric Patients: A Survey of Physicians and Pharmacists in Hong Kong.

Authors:  Twinny Cheuk Hin Chow; Janice Yuen Shun Li; Jasper Chak Ling Wong; Freddie Man Hong Poon; Hugh Simon Lam; Teddy Tai-Ning Lam; Chui Ping Lee; Celeste Lom-Ying Ewig; Yin Ting Cheung
Journal:  Front Pediatr       Date:  2020-11-30       Impact factor: 3.418

Review 5.  Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review.

Authors:  Marta Mejías-Trueba; Marta Alonso-Moreno; Laura Herrera-Hidalgo; Maria Victoria Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2021-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.